Jiudian Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 160 million yuan, a decrease of 45.21% compared with the same period last year. Total operating revenue was 1.287 billion yuan, down 14.89% year-on-year; net cash inflow from operating activities was 307 million yuan. The latest gross margin was 64.26%, a decrease of 10.32 percentage points from the same period last year; the latest return on equity was 6.15%, down 5.10 percentage points year-on-year. Diluted earnings per share were 0.40 yuan, down 32.20% year-on-year.
Hunan Jiudian Pharmaceutical Co LtdNet profit fell 45.21% year-on-year, revenue down 14.89%, margins and ROE declined.